The claim used elements from the Pfizer-BioNTech clinical trial protocol as evidence that the population received a different vaccine than the one tested in the trial. However, it overlooked other information available in reports from the European Medicines Agency. 2/4

These reports show that the vaccine manufacturing processes used for clinical trials and for the general population both yielded comparable vaccines. The EMA reports show that 3/4